InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.77
(
0.00%
)
Bitcoin
63,851.55
(
-0.06%
)
Post# of 751
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

fuzzy

Send PM Follow Ignore
Followers 10
Posts 3104
Boards Moderated 1
Alias Born 04/20/2001

fuzzy

Member Level

Re: None

Sunday, 07/24/2016 8:31:50 AM

Sunday, July 24, 2016 8:31:50 AM

Post# of 751
AbbVie (ABBV), also reporting Friday, is still ahead of its potential patent cliff, but it's already fighting to keep biosimilar versions of its best-selling Humira off the market. Analysts estimate that it grew in Q2 but at a slower rate than the previous quarter -- 11% on earnings and 13% on sales.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent ABBV News
More ABBV News
InvestorsHub NewsWire

NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM

ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM

Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM

Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM

Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM

Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM

Start posting your company's news
Only $200 per official company press release!